A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice.
Identifieur interne : 000703 ( PubMed/Checkpoint ); précédent : 000702; suivant : 000704A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice.
Auteurs : Mahmoud M. Shehata [Égypte] ; Ahmed Kandeil [Égypte] ; Ahmed Mostafa [Égypte] ; Sara H. Mahmoud [Égypte] ; Mokhtar R. Gomaa [Égypte] ; Rabeh El-Shesheny [Égypte] ; Richard Webby [États-Unis] ; Ghazi Kayali [États-Unis] ; Mohamed A. Ali [Égypte]Source :
- Pathogens (Basel, Switzerland) [ 2076-0817 ] ; 2019.
Abstract
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736-761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses.
DOI: 10.3390/pathogens8040281
PubMed: 31810359
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31810359Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice.</title><author><name sortKey="Shehata, Mahmoud M" sort="Shehata, Mahmoud M" uniqKey="Shehata M" first="Mahmoud M" last="Shehata">Mahmoud M. Shehata</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Kandeil, Ahmed" sort="Kandeil, Ahmed" uniqKey="Kandeil A" first="Ahmed" last="Kandeil">Ahmed Kandeil</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Mostafa, Ahmed" sort="Mostafa, Ahmed" uniqKey="Mostafa A" first="Ahmed" last="Mostafa">Ahmed Mostafa</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Mahmoud, Sara H" sort="Mahmoud, Sara H" uniqKey="Mahmoud S" first="Sara H" last="Mahmoud">Sara H. Mahmoud</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Gomaa, Mokhtar R" sort="Gomaa, Mokhtar R" uniqKey="Gomaa M" first="Mokhtar R" last="Gomaa">Mokhtar R. Gomaa</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="El Shesheny, Rabeh" sort="El Shesheny, Rabeh" uniqKey="El Shesheny R" first="Rabeh" last="El-Shesheny">Rabeh El-Shesheny</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name><affiliation wicri:level="2"><nlm:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105</wicri:regionArea><placeName><region type="state">Tennessee</region></placeName></affiliation></author><author><name sortKey="Kayali, Ghazi" sort="Kayali, Ghazi" uniqKey="Kayali G" first="Ghazi" last="Kayali">Ghazi Kayali</name><affiliation wicri:level="2"><nlm:affiliation>Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Ali, Mohamed A" sort="Ali, Mohamed A" uniqKey="Ali M" first="Mohamed A" last="Ali">Mohamed A. Ali</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31810359</idno><idno type="pmid">31810359</idno><idno type="doi">10.3390/pathogens8040281</idno><idno type="wicri:Area/PubMed/Corpus">000341</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000341</idno><idno type="wicri:Area/PubMed/Curation">000341</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000341</idno><idno type="wicri:Area/PubMed/Checkpoint">000703</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000703</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice.</title><author><name sortKey="Shehata, Mahmoud M" sort="Shehata, Mahmoud M" uniqKey="Shehata M" first="Mahmoud M" last="Shehata">Mahmoud M. Shehata</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Kandeil, Ahmed" sort="Kandeil, Ahmed" uniqKey="Kandeil A" first="Ahmed" last="Kandeil">Ahmed Kandeil</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Mostafa, Ahmed" sort="Mostafa, Ahmed" uniqKey="Mostafa A" first="Ahmed" last="Mostafa">Ahmed Mostafa</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Mahmoud, Sara H" sort="Mahmoud, Sara H" uniqKey="Mahmoud S" first="Sara H" last="Mahmoud">Sara H. Mahmoud</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Gomaa, Mokhtar R" sort="Gomaa, Mokhtar R" uniqKey="Gomaa M" first="Mokhtar R" last="Gomaa">Mokhtar R. Gomaa</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="El Shesheny, Rabeh" sort="El Shesheny, Rabeh" uniqKey="El Shesheny R" first="Rabeh" last="El-Shesheny">Rabeh El-Shesheny</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author><author><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name><affiliation wicri:level="2"><nlm:affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105</wicri:regionArea><placeName><region type="state">Tennessee</region></placeName></affiliation></author><author><name sortKey="Kayali, Ghazi" sort="Kayali, Ghazi" uniqKey="Kayali G" first="Ghazi" last="Kayali">Ghazi Kayali</name><affiliation wicri:level="2"><nlm:affiliation>Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Ali, Mohamed A" sort="Ali, Mohamed A" uniqKey="Ali M" first="Mohamed A" last="Ali">Mohamed A. Ali</name><affiliation wicri:level="1"><nlm:affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622</wicri:regionArea><wicri:noRegion>Cairo 12622</wicri:noRegion></affiliation></author></analytic><series><title level="j">Pathogens (Basel, Switzerland)</title><idno type="ISSN">2076-0817</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736-761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31810359</PMID><DateRevised><Year>2020</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">E281</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens8040281</ELocationID><Abstract><AbstractText>Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736-761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shehata</LastName><ForeName>Mahmoud M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandeil</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahmoud</LastName><ForeName>Sara H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomaa</LastName><ForeName>Mokhtar R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Shesheny</LastName><ForeName>Rabeh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webby</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayali</LastName><ForeName>Ghazi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Link, Baabda 1109, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201400006C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5175</GrantID><Agency>Science and Technology Development Fund</Agency><Country></Country></Grant><Grant><GrantID>TT110801</GrantID><Agency>National Research Centre</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">H1N1pdm</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">influenza vaccine</Keyword><Keyword MajorTopicYN="N">reverse genetics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31810359</ArticleId><ArticleId IdType="pii">pathogens8040281</ArticleId><ArticleId IdType="doi">10.3390/pathogens8040281</ArticleId><ArticleId IdType="pmc">PMC6963271</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccines (Basel). 2019 May 28;7(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">31141982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10801978</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viruses. 2018 Sep 13;10(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">30217093</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Nov;87(21):11950-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23986586</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Med. 2016 Jun;10(2):120-36</Citation><ArticleIdList><ArticleId IdType="pubmed">26791756</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viral Immunol. 2014 Dec;27(10):543-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25387086</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2006 Feb 5;345(1):73-87</Citation><ArticleIdList><ArticleId IdType="pubmed">16271378</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Immunol. 2019 Jan 29;9:3103</Citation><ArticleIdList><ArticleId IdType="pubmed">30761157</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2012 Dec;93(Pt 12):2564-2574</Citation><ArticleIdList><ArticleId IdType="pubmed">22956735</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2016 Mar;97(3):620-631</Citation><ArticleIdList><ArticleId IdType="pubmed">26743314</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Rep. 2018 Jan 2;22(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">29298413</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2017 Apr;140:55-61</Citation><ArticleIdList><ArticleId IdType="pubmed">28040513</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2014 Jul;95(Pt 7):1444-1463</Citation><ArticleIdList><ArticleId IdType="pubmed">24722680</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2018;14(12):2964-2970</Citation><ArticleIdList><ArticleId IdType="pubmed">30024831</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 Oct 14;32(45):5975-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25192975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2014 Mar 04;5(2):e00031-14</Citation><ArticleIdList><ArticleId IdType="pubmed">24595369</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viruses. 2019 Mar 02;11(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">30832356</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Jun 20;324(1):67-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15183054</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2017 Jul 3;13(7):1615-1624</Citation><ArticleIdList><ArticleId IdType="pubmed">28277821</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4928-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24639495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MMWR Recomm Rep. 2019 Aug 23;68(3):1-21</Citation><ArticleIdList><ArticleId IdType="pubmed">31441906</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2018 Feb;150:30-38</Citation><ArticleIdList><ArticleId IdType="pubmed">29246504</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Infect Dis. 2019 Feb 4;19(1):113</Citation><ArticleIdList><ArticleId IdType="pubmed">30717685</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioengineered. 2013 Jan-Feb;4(1):9-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22922205</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2011 Feb 17;29(9):1836-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21199698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Égypte</li><li>États-Unis</li></country><region><li>Tennessee</li><li>Texas</li></region></list><tree><country name="Égypte"><noRegion><name sortKey="Shehata, Mahmoud M" sort="Shehata, Mahmoud M" uniqKey="Shehata M" first="Mahmoud M" last="Shehata">Mahmoud M. Shehata</name></noRegion><name sortKey="Ali, Mohamed A" sort="Ali, Mohamed A" uniqKey="Ali M" first="Mohamed A" last="Ali">Mohamed A. Ali</name><name sortKey="El Shesheny, Rabeh" sort="El Shesheny, Rabeh" uniqKey="El Shesheny R" first="Rabeh" last="El-Shesheny">Rabeh El-Shesheny</name><name sortKey="Gomaa, Mokhtar R" sort="Gomaa, Mokhtar R" uniqKey="Gomaa M" first="Mokhtar R" last="Gomaa">Mokhtar R. Gomaa</name><name sortKey="Kandeil, Ahmed" sort="Kandeil, Ahmed" uniqKey="Kandeil A" first="Ahmed" last="Kandeil">Ahmed Kandeil</name><name sortKey="Mahmoud, Sara H" sort="Mahmoud, Sara H" uniqKey="Mahmoud S" first="Sara H" last="Mahmoud">Sara H. Mahmoud</name><name sortKey="Mostafa, Ahmed" sort="Mostafa, Ahmed" uniqKey="Mostafa A" first="Ahmed" last="Mostafa">Ahmed Mostafa</name></country><country name="États-Unis"><region name="Tennessee"><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name></region><name sortKey="Kayali, Ghazi" sort="Kayali, Ghazi" uniqKey="Kayali G" first="Ghazi" last="Kayali">Ghazi Kayali</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000703 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000703 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31810359
|texte= A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31810359" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |